Pages that link to "Q37358267"
Jump to navigation
Jump to search
The following pages link to Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro (Q37358267):
Displaying 50 items.
- Bisphosphonates in the adjuvant setting of breast cancer therapy--effect on survival: a systematic review and meta-analysis (Q21132670) (← links)
- Development of bisphosphonates (Q21195188) (← links)
- Direct effects of bisphosphonates on breast cancer cells (Q24802079) (← links)
- Actions of bisphosphonates in animal models of breast cancer (Q24802119) (← links)
- Bisphosphonates as anticancer agents in early breast cancer: preclinical and clinical evidence (Q26795493) (← links)
- Bisphosphonates in breast cancer (Q26859326) (← links)
- Bisphosphonates induce apoptosis in human breast cancer cell lines (Q28344185) (← links)
- Bisphosphonates regulate cell growth and gene expression in the UMR 106-01 clonal rat osteosarcoma cell line (Q28361973) (← links)
- The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel (Q28362972) (← links)
- Breast cancer metastasis to bone: mechanisms of osteolysis and implications for therapy (Q30437441) (← links)
- Ibandronate treatment decreases the effects of tumor-associated lesions on bone density and strength in the rat. (Q31034846) (← links)
- A newly developed bisphosphonate, YM529, is a potent apoptosis inducer of human myeloma cells (Q31801512) (← links)
- Alendronate decreases orthotopic PC-3 prostate tumor growth and metastasis to prostate-draining lymph nodes in nude mice (Q33326045) (← links)
- Anti-tumour activity of bisphosphonates in human myeloma cells. (Q33536291) (← links)
- Influence of zoledronic acid on disseminated tumor cells in bone marrow and survival: results of a prospective clinical trial (Q33587199) (← links)
- Bone-in-culture array as a platform to model early-stage bone metastases and discover anti-metastasis therapies (Q33628894) (← links)
- Zoledronic acid effectiveness against breast cancer metastases - a role for estrogen in the microenvironment? (Q33739204) (← links)
- The biology and management of bone metastases (Q33757655) (← links)
- New bisphosphonates in the treatment of bone diseases (Q33785411) (← links)
- Bisphosphonates: from grandparents to grandchildren (Q33807859) (← links)
- Antitumour effects of bisphosphonates: first evidence and possible mechanisms (Q33897197) (← links)
- Bisphosphonates in the adjuvant treatment of cancer: experimental evidence and first clinical results. International Bone and Cancer Study Group (IBCG). (Q33898576) (← links)
- The potential role of bisphosphonates as adjuvant therapy in the prevention of bone metastases (Q33970557) (← links)
- Bisphosphonates and the prevention of metastasis: first evidences from preclinical and clinical studies (Q33970595) (← links)
- Cancer and Bone* (Q34066060) (← links)
- The role of zoledronic acid in the adjuvant treatment of breast cancer: current perspectives (Q34145863) (← links)
- Isolation and characterization of chondrolectin (Chodl), a novel C-type lectin predominantly expressed in muscle cells. (Q34192419) (← links)
- Circulating tumor cell count during zoledronic acid treatment in men with metastatic prostate cancer: a pilot study (Q34294905) (← links)
- The role of bisphosphonates as adjuvant therapy for breast cancer (Q34397795) (← links)
- Strategies for management of prostate cancer-related bone pain (Q34558618) (← links)
- Adjuvant therapy with zoledronic acid in patients with breast cancer: a systematic review and meta-analysis (Q34583705) (← links)
- Complementary therapies for reducing the risk of osteoporosis in patients receiving luteinizing hormone-releasing hormone treatment/orchiectomy for prostate cancer: a review and assessment of the need for more research (Q34591103) (← links)
- NCCN Task Force Report: Bone Health in Cancer Care (Q34617936) (← links)
- Clodronate: mechanisms of action on bone remodelling and clinical use in osteometabolic disorders (Q35000983) (← links)
- The anti-tumour activity of bisphosphonates. (Q35019664) (← links)
- The use of bisphosphonates in patients with breast cancer (Q35039488) (← links)
- Antitumor effects of bisphosphonates (Q35053955) (← links)
- Current and future status of adjuvant therapy for breast cancer (Q35053975) (← links)
- The potential role of bisphosphonates in prostate cancer (Q35081743) (← links)
- Cytotoxic effect of clodronate and zoledronate on the chondrosarcoma cell lines HTB-94 and CAL-78 (Q35197773) (← links)
- Tumour macrophages as potential targets of bisphosphonates. (Q35547309) (← links)
- The anti-tumor potential of zoledronic acid (Q35601657) (← links)
- Injectable bisphosphonates in the treatment of postmenopausal osteoporosis (Q35602572) (← links)
- In vitro synergistic cytoreductive effects of zoledronic acid and radiation on breast cancer cells (Q35605757) (← links)
- Advances in the use of bisphosphonates in the prostate cancer setting (Q35679766) (← links)
- Bisphosphonates and bone metastases: current status and future directions (Q36118409) (← links)
- Zoledronic acid exerts its antitumor effect in multiple myeloma interfering with the bone marrow microenvironment (Q36194583) (← links)
- Adjuvant pamidronate therapy prevents the development of bone metastases in breast cancer patients with four or more positive nodes (Q36216730) (← links)
- Skeletal complications of prostate cancer: pathophysiology and therapeutic potential of bisphosphonates (Q36217148) (← links)
- Ibandronate: efficacy in the treatment of metastatic bone disease (Q36429562) (← links)